| Similar Articles |
|---|
 |
Chemistry World
December 24, 2015
Jennifer Newton |
AstraZeneca to buy Acerta for blood cancer drug AstraZeneca has agreed to buy a majority stake in Acerta Pharma, a privately-owned biopharmaceutical company based in the Netherlands and US.   |
Chemistry World
July 31, 2014
Phillip Broadwith |
AstraZeneca stocks respiratory and cancer pipelines AstraZeneca has agreed to buy Spanish firm Almirall's respiratory drug assets for $875 million up front, plus up to $1.2 billion in performance milestone payments. |
The Motley Fool
July 30, 2007
Brian Lawler |
AstraZeneca's Yawner of a Quarter The pharma's second-quarter results are ho-hum. Investors may do well to take a look at some of the other big pharma stocks, which offer more compelling reasons to buy. |
Chemistry World
December 20, 2013
Patrick Walter |
AstraZeneca shells out $4.1bn for diabetes business AstraZeneca has agreed to pay Bristol-Myers Squibb up to $4.1 billion for its share of the pharma giants' diabetes joint venture. |
Chemistry World
April 29, 2014
Phillip Broadwith |
Pfizer courts AstraZeneca megamerger US-based pharma behemoth Pfizer has publically announced its intention to make a merger offer to the UK's AstraZeneca, in a deal valued at around $100 billion. |
Chemistry World
August 3, 2015
Phillip Broadwith |
AstraZeneca sells off drugs to streamline portfolio Anglo-Swedish pharmaceutical firm AstraZeneca has agreed to sell the rights to two drugs that the company considers lie outside its strategic focus areas. |
The Motley Fool
May 21, 2009
Robert Steyer |
The AstraZeneca Dilemma Can AstraZeneca produce enough new drugs to offset a series of upcoming patent expirations? |
The Motley Fool
February 1, 2008
Brian Lawler |
AstraZeneca's Trying to Get Healthier Big pharma AstraZeneca tries to get back on track by reducing costs. |
The Motley Fool
October 26, 2006
Brian Lawler |
Market Rejects AstraZeneca's Remedy Investors pummel the pharmaceutical firm, despite its impressive results. |
Chemistry World
March 2, 2015
Phillip Broadwith |
AstraZeneca to spin off anti-infectives research The new company's principal asset will be the novel gyrase inhibitor AZD0914, which is currently in Phase II clinical trials for treating gonorrhea. |
The Motley Fool
April 30, 2010
Brian Orelli |
Living the Blockbuster Model AstraZeneca's top drugs provide top-line growth in the first quarter. |
The Motley Fool
October 27, 2005
Stephen D. Simpson |
AstraZeneca Prepares for a Dry Spell A weak late-stage pipeline will make for challenging earnings growth in the coming years. Investors may want to hold out for a better price here. |
Chemistry World
December 5, 2013
Phillip Broadwith |
Merck KGaA snaps up electronic materials specialist The speciality chemicals arm of Merck KGaA has agreed to buy out AZ Electronic Materials for 1.6 billion pounds in cash. |
Pharmaceutical Executive
October 1, 2005
Brad Miles |
Value Today for Drugs Tomorrow The industry can help its bad rep by communicating the promise of its pipeline -- and the value of its companies. |
The Motley Fool
July 27, 2006
Stephen D. Simpson |
AstraZeneca Needs a Rest The stock isn't too expensive, but it's no longer a bargain. |
Chemistry World
July 15, 2008
Hepeng Jia |
Testing Times for New Liver Drug AstraZeneca is set to start clinical trials of a liver cancer drug developed for Chinese patients. |
BusinessWeek
January 31, 2005
Kerry Capell |
No Relief For AstraZeneca More bad news about potential blockbusters weakens Europe's third-largest drugmaker. Analysts say the only thing keeping Astra's shares from going into free fall is the mounting speculation that GSK might make a play for the troubled drugmaker. |
The Motley Fool
December 1, 2008
Brian Orelli |
It's Wait Until Next Year for These Drugmakers Drugs from AstraZeneca and Eli Lilly face delays because of the FDA. Both plan to resubmit their applications for approval in the first half of next year, but the delays likely will have different effects on the companies. |
Chemistry World
May 7, 2013
Phillip Broadwith |
AstraZeneca site to become biotech hub The first three companies have already moved in, and more will hopefully follow to fill the space left by AZ as it relocates to Cambridge, UK. |
The Motley Fool
January 27, 2005
Stephen D. Simpson |
AstraZeneca Shines, for Now The British-Swedish drug company has a great quarter, but the future looks dimmer. |
Chemistry World
January 28, 2010
Nina Notman |
AstraZeneca's workforce slashed again Pharma giant AstraZeneca is to cut another 8,000 jobs globally over the next four years - with approximately 1,800 additional research and development staff to be lost. |
Chemistry World
January 30, 2014
Phillip Broadwith |
AstraZeneca ends R&D in India Pharmaceutical firm AstraZeneca is quitting its R&D site in Bangalore, India. |
Chemistry World
June 10, 2013
Phillip Broadwith |
AstraZeneca stocks pipeline with acquisitions AZ is also buying Omthera Pharmaceuticals for an up-front payment of $323 million, with a potential $120 million in milestone payments on offer. |
Chemistry World
May 19, 2014
Phillip Broadwith |
AstraZeneca refuses Pfizer's 'final' offer The US giant has described this proposal, valuing AZ at 70 billion pounds, as 'final' and says it 'cannot be increased'. |
Chemistry World
April 24, 2007
Victoria Gill |
AstraZeneca Scoops up $15.6 Billion Vaccine Business AstraZeneca has joined the race to scoop up acquisition opportunities in the biologics sector with a $15.6 billion deal to buy U.S. vaccines and biotechnology company MedImmune. |
The Motley Fool
October 30, 2009
Brian Orelli |
Of One-Time Gains and Pipelines AstraZeneca's earnings report illustrates the nature of polar opposites with one-time gains and new drugs. One is to be largely ignored, while the other will drive the drugmaker's future. |
The Motley Fool
April 26, 2007
Brian Lawler |
AstraZeneca's Announcement Overshadows Earnings AstraZeneca releases first-quarter financial results. Investors, take note. |
The Motley Fool
July 30, 2010
Cliff D'Arcy |
Which Is the Better Big Pharma? AstraZeneca is having a good 2010 -- and its shares are enjoying a great run, too. Here's how it compares to GlaxoSmithKline. |
Chemistry World
May 14, 2014
Andy Extance |
Pfizer presses hard for AstraZeneca deal US pharma giant Pfizer is battling a backlash of suspicion and hostility across the world over its attempts to acquire its UK-headquartered rival AstraZeneca. |
The Motley Fool
October 11, 2011
Cliff D'Arcy |
AstraZeneca Loves This $100Bn Market The British pharma firm makes its largest-ever manufacturing investment -- in China. |
Chemistry World
December 10, 2014 |
Big pharma opens up abandoned drugs Sixty eight stalled pharmaceutical compounds are being made available for academic research through the UK Medical Research Council. |
The Motley Fool
September 30, 2011
David Williamson |
This Week in Health Care Pharma news about Pfizer, AstraZeneca, and the multibillion-dollar battle to replace the maligned blood-thinner warfarin. |
The Motley Fool
February 2, 2006
Stephen D. Simpson |
AstraZeneca: Of Patents and Pipelines Losing Toprol-XL would be a blow, but not a fatal one. So what to do with AstraZeneca's stock? It might not be as cheap as Pfizer or Abbott Labs, but if the pipeline works out, it still seems like there's money to be made here. |
The Motley Fool
December 28, 2005
Stephen D. Simpson |
AstraZeneca, Reloaded In an attempt to shore up a soft pipeline, AstraZeneca has gotten very busy looking for partners. Investors, this is not the most attractive stock in the sector, but not a horrible pick, either. |
The Motley Fool
January 28, 2011
Alan Oscroft |
AstraZeneca to Double Buybacks Regulatory setbacks have hit the drug firm's profits, but things look pretty resilient overall. |
Chemistry World
May 28, 2014
Phillip Broadwith |
Time called on Pfizer -- AstraZeneca deal Pfizer's pursuit of a pharmaceutical megamerger has concluded with the US giant withdrawing its final offer two hours before the deadline set by the UK's takeover rules. |
The Motley Fool
October 14, 2010
Sean Williams |
Should You Let AstraZeneca Go? Multiple drug patent expirations await. It's time to run away. |
The Motley Fool
November 2, 2011
Prabhat Sakya |
AstraZeneca vs. GlaxoSmithKline If you could only invest in one of these companies, which would it be? |
